VYGR - Voyager Therapeutics: On Track To Deliver High Returns On Investment

2024-03-13 13:11:39 ET

Summary

• The company's strength lies in its TRACER capsids technology that can deliver therapeutic molecules to the brain, leading to multimillion-dollar deals with pharmaceutical giants, such as Novartis.
• Despite the risks and uncertainties, long-term investors may be rewarded once the company's products reach clinical trial validation.
• Voyager’s investors should expect share price volatility. Nonetheless, based on my financial valuation and the potential upsides, I consider this company as a “buy”.

In this article, I will be providing a financial and scientific analysis of Voyager Therapeutics Inc. ( VYGR ). Financially speaking, Voyager is still due to live up to its expectations, which might be one of the reasons for their common stock share price volatility: losing -7.5% between February 28th, 2024 (earnings release day) and February 29th, 2024, bouncing back up 15.87% until March 4th, when they started to trend down again, with the share price standing at USD 9.23 at the moment of writing this article....

For further details see: